Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 5Breast Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 3Melanoma 3Leukemia, Myeloid, Acute 3Leukemia 3Carcinoma, Non-Small-Cell Lung 3Myelodysplastic Syndromes 2Lymphoma, Mantle-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Craniopharyngioma 2COVID-19 2Burkitt Lymphoma 2Arthritis, Rheumatoid 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Unresectable Pancreatic Carcinoma 1Triple Negative Breast Neoplasms 1Stroke 1Sarcoma 1Respiratory Tract Infections 1Recurrence 1Pulmonary Disease, Chronic Obstructive 1Prostatic Neoplasms 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

tocilizumab 1Probiotics 1Paclitaxel 1Cisplatin 1Carboplatin 1Antineoplastic Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Cancer Therapy-related Cardiovascular Toxicity × tocilizumab × Clear all
NCT05730777 2023-02-16

Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics

Peking University Third Hospital

Phase 4 Unknown
200 enrolled

Cancer Therapy-related Cardiovascular Toxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡